Richard Nolan Townsend - Jan 7, 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: Chief Executive Officer, Director
Signature: /s/ Youjin Choi, Attorney-in-Fact
Stock symbol: LXEO
Transactions as of: Jan 7, 2025
Transactions value $: $0
Form type: 4
Date filed: 1/10/2025, 04:55 PM
Previous filing: Dec 12, 2024
Next filing: Feb 21, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXEO	Common Stock	Award	$0	+104K	+85.96%	$0.00	224K	Jan 7, 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXEO	Stock Option (right to buy)	Award	$0	+208K		$0.00	208K	Jan 7, 2025	Common Stock	208K	$7.33	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2	Includes 147,500 RSUs.
F3	25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.